XBIO Profile
Xenetic Biosciences, Inc., a pioneering biopharmaceutical company, specializes in the development of innovative cancer therapies using its advanced XCART technology. The company’s XCART platform focuses on creating personalized chimeric antigen receptor T cell (CAR T) therapies tailored to target specific tumor neoantigens unique to each patient. This personalized approach aims to enhance the precision and effectiveness of cancer treatment by directly targeting patient-specific cancer cells with high accuracy.
In addition to its XCART technology, Xenetic is dedicated to the discovery and development of biologic drugs and oncology therapeutics. The company’s research and development efforts are centered on advancing cell-based therapies that specifically target the B-cell receptor present on malignant tumor cells. These therapies are particularly aimed at treating B-cell lymphomas, a type of cancer that affects the immune system's B cells. By focusing on targeted treatments, Xenetic seeks to offer more effective and less toxic alternatives to conventional cancer therapies.
Xenetic also leverages its proprietary PolyXen platform, a cutting-edge drug delivery technology designed to enhance the efficacy and stability of biologic drugs. This platform is utilized in collaborations with leading biotechnology and pharmaceutical companies to develop improved drug formulations and delivery mechanisms. The company has established strategic partnerships with prominent organizations, including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC, to advance its technological innovations and expand its impact in the pharmaceutical industry.
Founded and headquartered in Framingham, Massachusetts, Xenetic Biosciences, Inc. continues to be at the forefront of biopharmaceutical innovation. Its commitment to developing personalized and targeted therapies, coupled with its strategic collaborations, positions the company as a significant player in the advancement of cancer treatment and drug delivery technologies.
|
